A
Autobahn Therapeutics
Focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body
About Autobahn Therapeutics
Autobahn Therapeutics is a biopharmaceutical startup that operates in the healthcare sector, specifically focusing on the development of innovative therapies for central nervous system (CNS) disorders. The company's mission is to improve the health and quality of life for people affected by these disorders by harnessing the regenerative power of the human body.
The company's business model revolves around the development and commercialization of its proprietary brain-targeting chemistry platform. This platform enables the creation of orally administered small molecule prodrugs, which are drugs that are metabolized into pharmacologically active compounds in the body. These prodrugs have tunable ratios of central versus peripheral exposure, allowing for the development of molecules with distribution profiles tailored to match the pathophysiology of specific diseases.
Autobahn Therapeutics serves a broad market of patients affected by CNS disorders, a group that includes conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis, among others. The company generates revenue through the development, clinical testing, and eventual commercialization of its therapeutic products.
The company's portfolio is anchored by programs that leverage established clinical precedence, human genetics, and biology. This approach helps to de-risk their pipeline and accelerate early development. The company also utilizes biomarker-driven development strategies to demonstrate on-target/on-tissue activity and proof-of-mechanism early in the clinic.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 80.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2024 | $100M | $400M | Invus · BVF Partners · Section 32 · Samsara BioCapital | ↗ |
| LATE VCOther financing | Sep 2022 | $33M | $380M | Bristol-Myers Squibb · ARCH Venture Partners · BVF Partners · GT Healthcare | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Autobahn Therapeutics is 2.8K monthly website visits, up 33.3% over the last three months. Autobahn Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
ARCH Venture Partners
Cowen Group
Bristol-Myers Squibb
BVF Partners- PVPfizer Ventures
Biogen
Invus
Alexandria Venture Investments
Section 32
Samsara BioCapital
Series B and later6 investors entered at this stage
GT Healthcare
Newpath Partners
Blue Owl Capital
Insight Partners
Canaan
Monograph Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Autobahn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Autobahn Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.